)
)
)
Polymed Biopharmaceuticals, Inc
Polymed Biopharmaceuticals is seeking strategic partners to advance our pipeline of optimized PROTACs and DACs (KRAS G12D) as well as our clinic-ready asset having an FDA-cleared IND targeting FLT3 and IRAK4 for patients with AML and MDS.
Polymed is a part of the J&J JLABS Innovation Network with global operations based in Hangzhou, Shanghai, and Cambridge, MA.
Polymed partnered with Photys Therapeutics (Waltham, MA) in February 2025 to develop our best-in-class oral IRAK PROTAC for autoimmune conditions.
Address
MassachusettsUnited States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)